OraSure Technologies Appoints New Senior Vice President, Business Development

BETHLEHEM, Pa., April 10, 2018 -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that David Rappaport has been appointed as the Company’s new Senior Vice President, Business Development.

Prior to joining OraSure, Mr. Rappaport served as Senior Vice President, Healthcare Investment Banking at Raymond James & Associates where he provided investment banking services in the Life Sciences practice group.  Prior to his tenure at Raymond James, Mr. Rappaport served as a healthcare investment banker with Inverness Advisors, Thomas Weisel Partners and SG Cowen.  Mr. Rappaport received a Bachelors of Business Administration in Finance and Economics from the University of Wisconsin - Madison and an MBA from Emory University.

“We are pleased that David will be heading up our business development function,” said Stephen S. Tang, Ph.D., President and CEO of OraSure Technologies.  “The identification, evaluation and acquisition of new products, businesses and technologies will be a key priority as we continue to build our business.  David’s strong investment banking experience in the life sciences field is an ideal background for him to lead our M&A activities and contribute to the development and execution of our strategic business plans.  I look forward to working with David as we execute against our strategic priorities.”

About OraSure Technologies

OraSure Technologies is a leader in the development, manufacture and distribution of point of care diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. Its first-to-market, innovative products include rapid tests for the detection of antibodies to HIV and HCV on the OraQuick^® platform, oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications, and oral fluid laboratory tests for detecting various drugs of abuse. OraSure's portfolio of products is sold globally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, research and academic institutions, distributors, government agencies, physicians' offices, commercial and industrial entities and consumers. The Company's products enable healthcare providers to deliver critical information to patients, empowering them to make decisions to improve and protect their health. For more information on OraSure Technologies, please visit www.orasure.com.

Company contact: